Tue, Sep 23, 2014, 4:37 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Neostem, Inc. Message Board

franwurl 4 posts  |  Last Activity: Aug 29, 2014 5:10 PM Member since: Jul 29, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • franwurl franwurl Aug 29, 2014 5:10 PM Flag

    An Intercept pathogen deactivating dialysis device might be useful as a conjunctive treatment not just for Ebola, Marburg and possibly other viremias but also for bacterial septicemias.

  • franwurl franwurl Aug 28, 2014 7:32 PM Flag

    These are interesting ideas that would require experimentation with primates first. But another approach might be apheris, that is extracorporeal whole blood perfusions through an Intercept device deactivating Ebola. If Ebola sequesters in the spleen (who knows where Ebola sequesters?) over the time span of several hours Ebola might be effectively killed. It would be interesting to apply this approach in primates.

  • Reply to

    Baxter?

    by thomtidom Aug 25, 2014 3:48 PM
    franwurl franwurl Aug 28, 2014 7:14 PM Flag

    http://clinicaltrials.gov/ct2/show/NCT01508910
    The purpose of the study is to assess the safety and efficacy of targeted intramyocardial delivery of Auto-CD34+ cells for increasing exercise time and amelioration of anginal symptoms in subjects with refractory angina and chronic myocardial ischemia.

    This study is ongoing, but not recruiting participants. This seems curious because my understanding was that this study ended coincidentally about the same time as the PreSERVE NBS study. Results should be forthcoming soon.

  • Reply to

    AMR-001 not good enough?

    by filosofer989 Aug 24, 2014 11:03 AM
    franwurl franwurl Aug 24, 2014 3:27 PM Flag

    ASTM heart failure results suggest positive PreRESERVE results
    http://seekingalpha.com/currents/post/1949495?source=ipadportfolioapp_email
    Although results were not statistically significant in part probably because the study was not sufficiently powered, there was a major reduction of major adverse cardiovascular events for ischemic DCM patients treated with ixmyelocel-T. ASTM rose over 7% on the news. Like the Zeiher and other studies this evidence is supportive of AMR-001 results being positive. It is doubtful that news has been leaked. The volume does not support such a conclusion.

NBS
5.26+0.03(+0.57%)4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.